The company's principal activity is to develop and commercialize pulsatile drug products which is used in the treatment of infectious disease. It has developed a proprietary technology called pulsys based on the biological finding that bacteria exposed to antibiotics in front-loaded, sequential bursts, or pulses, are killed more efficiently and effectively than those exposed to standard antibiotic treatment regimens.
